Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes

• Published in: Heart rhythm Vol. 11; no. 8; pp. 1441 - 1445
• Main Authors: Shinohara, Tetsuji, MD, PhD, Ebata, Yuki, MD, Ayabe, Reika, MD, Fukui, Akira, MD, PhD, Okada, Norihiro, MD, PhD, Yufu, Kunio, MD, PhD, Nakagawa, Mikiko, MD, PhD, Takahashi, Naohiko, MD, PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2014
• Subjects: Adult; Anti-Arrhythmia Agents - administration & dosage; Bepridil; Bepridil - administration & dosage; Cardiovascular; Cilostazol; Death, Sudden, Cardiac - epidemiology; Death, Sudden, Cardiac - prevention & control; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Humans; J-wave syndrome; Male; Phosphodiesterase 3 Inhibitors - administration & dosage; Recurrence; Tetrazoles - administration & dosage; Treatment Outcome; Ventricular fibrillation; Ventricular Fibrillation - drug therapy; Ventricular Fibrillation - physiopathology; Young Adult; ventricular fibrillation; BrS; early repolarization syndrome; J-wave syndrome; Brugada syndrome; ERS; ECG; transient outward current; Cilostazol; ICD; cAMP; electrocardiography; VF; I to; cyclic adenosine monophosphate; I Ca; Bepridil; implantable cardioverter-defibrillator; inward calcium current; Ito; ICa; Ventricular fibrillation

Background Brugada syndrome and idiopathic ventricular fibrillation (VF) associated with inferolateral early repolarization patterns are termed “J-wave syndromes.” In such patients, an implantable cardioverter-defibrillator (ICD) is first-line therapy for prevention of sudden cardiac death. However,...